Biomedical subjects

J Garot

Publications and source records attributed to J Garot.

26 records · Page 2Linked to original sources

PubMed1999

[Ultrasonic imaging of coronary atherosclerosis].

Intra-coronary ultrasonography (ICV) is a technique for in vivo study of the different layers of the arterial wall, the site of atherosclerosis. A qualitative analysis of the composition of the plaque can predict its potential evolutivity (chronic with slow progression or at risk of rupture and causing acute thrombosis) and its response to different types of angioplasty, which could eventually become and essential factor in the choice of appropriate therapeutic strategy. Analysis of the results of B mode ultrasonic scanning has provided correlations with the histological composition of the arterial wall, validating the method and opening up the field of tissue characterisation which hitherto had been limited by the absence of sufficiently reliable, accurate and reproducible quantitative parameters. Magnetic resonance imaging (MRI) is a complementary, non-invasive tool for tissue analysis because its sensitivity to the biophysical and biochemical properties of tissues which makes it a promising method of morphological and functional imaging. Other methods of imaging atheromatous plaques include angioscopy and optic coherence tomography which have also contributed to the improvement in our knowledge of atherosclerosis. These methods of imaging which are slowly overcoming their limitations provide documents which ressemble more and more the histological appearances. Intracoronary ultrasonography is the most promising method and raises hopes that one day we shall be able to predict the outcome and anticipate the risk of rupture of atherosclerotic plaques.

Coronary Artery Disease↗

PubMed1999

[Intra-coronary ultrasonography during angioplastic procedures].

Thanks to miniaturization and constant improvement of technologies, intracoronary ultrasound (ICUS) progressively takes its place as the best tool to accurately analyze arterial wall structure. However, its routine use during interventional procedures remains limited. ICUS provides precious informations, complementary to angiography, and guide interventional procedures on the basis of a more accurate analyze of the components of the plaque, thus improving their success rate. Since its use favorized the understanding of the different devices mechanisms (angioplasty, stents, directional and rotational atherectomy), ICUS contributed to reduce the incidence of their complications. Many studies have emphasized ICUS interest during these procedures: their results seem to be significantly improved by the way of prompting the operator to adopt an aggressive strategy (additional inflations using high pressures, combination of different techniques...) which tend to reduce the complication rate and the restenosis incidence. Actually, the restenosis rate was in all these studies [OARS (29%), ABACAS (21%) and MUSIC (8.3%)] directly associated to ICUS parameters measured immediately after treatment, particularly the residual plaque burden. Whether its use, that engender substantial cost, cannot be systematic, trained centers will probably demonstrate that a rational and suitable use lead to adopt optimal strategies and achieve improved results.

Angioplasty, Balloon, Coronary↗

PubMed1999

[Diagnostic value of endocoronary echography].

Intracoronary ultrasound allows in vivo examination of the various layers of the wall of arteries affected by atherosclerosis. Its use in the catheterisation laboratory has therefore allowed better understanding of the mechanism of the action of the various angioplasty procedures, allowing better guidance of the indications and better control of these techniques. It also helps to guide these procedures, thereby facilitating an optimal immediate result, which determines the long-term outcome. The characteristics of intracoronary ultrasound (high resolution, proximity of the arterial wall, echogenicity of constituents of the plaque) make it the instrument of choice to study the composition and structure of the plaque, which determine the clinical presentation and active potential, especially the risk of complications (rupture). The development of image and crude acoustic signal processing techniques have improved the performance of the analysis of these documents and raise hopes of one day being able to predict and anticipate plaque rupture.

Angioplasty↗

PubMed1998

Effects of the 14F hemopump on coronary hemodynamics in patients undergoing high-risk coronary angioplasty.

BACKGROUND: The influence of the 14F Hemopump on coronary hemodynamics in patients with coronary artery disease remains unknown. METHODS: Systemic and coronary hemodynamic measurements were obtained in eight patients among 13 who underwent high-risk coronary angioplasty in our institution with the support of the Hemopump. Coronary blood flow velocity was measured with a 0.014-inch Doppler-tipped guide wire both proximal and distal to the target lesion. RESULTS: Angioplasty decreases the diameter coronary stenosis from 76% +/- 21% to 22% +/- 11%. Hemopump support did not change systemic hemodynamics either before or after angioplasty. During angioplasty Hemopump support decreased the pulmonary capillary wedge pressure from 23.5 +/- 8.5 mm Hg to 18.6 +/- 7 mm Hg (p = 0.013). No changes in either heart rate, mean and systolic aortic pressures, and cardiac index were observed throughout the procedure. After successful angioplasty was performed, the ratio of proximal to distal flow velocity decreased from 2.11 +/- 1 to 1.65 +/- 0.2 (p = 0.05). However, Hemopump did not affect absolute coronary blood flow velocities or the phasic pattern of flow velocities (diastolic systolic velocity ratio, diastolic and systolic velocity integrals) either in proximal or distal locations either before or after angioplasty. CONCLUSIONS: This study shows that although the 14F Hemopump produces unloading of the left ventricle, it does not importantly alter coronary hemodynamics when systemic hemodynamics are stable. Whether the Hemopump would maintain or improve coronary blood flow in compromised patients remains to be determined.

Aged↗

PubMed1998

Comparison of regional myocardial velocities assessed by quantitative 2-dimensional and M-mode color Doppler tissue imaging: influence of the signal-to-noise ratio of color Doppler myocardial images on velocity estimators of the Doppler tissue imaging system.

M-mode color Doppler imaging of the myocardium affords a greater sampling rate and signal-to-noise (S/N) ratio than 2-dimensional (2D) imaging. In this study, we compared myocardial velocities assessed by 2D and M-mode Doppler tissue imaging (DTI) at the same site and evaluated the influence of the S/N ratio on velocity estimates of the currently used DTI systems. In patients with and without impaired regional left ventricular function, myocardial velocities assessed by 2D DTI were lower than those obtained with M-mode DTI. The difference between regional velocities derived from both imaging techniques was positively correlated with the extent of the "black zone," which could be considered as indirectly reflecting the S/N ratio for each frame. Thus in the clinical setting and on currently used echocardiographs, 2D DTI may provide underestimated regional myocardial velocities when compared with M-mode, mainly because of the influence of the lower sampling rate and S/N ratio on velocity estimators of the imaging system.

Echocardiography, Doppler, Color↗

PubMed1998

[Therapeutic strategy of the management of acute heart failure].

Acute cardiac failure should be approached clinically and paraclinically as an emergency and precipitation is not always what is required. Consequently, strict clinical and paraclinical strategy leads to decisive action to improve the prognosis. The authors describe the principles of management of acute cardiac failure. The different stages which are carried out simultaneously in clinical practice are discussed: physiopathological basis, clinical and paraclinical investigations, symptomatic and aetiological treatment. The description and indications of circulatory assistance are considered. This constitutes a major therapeutic advance of the last decade and has changed the treatment of the most severe clinical forms of acute cardiac failure.

Acute Disease↗

PubMed1996

Effect of delayed percutaneous transluminal coronary angioplasty of occluded coronary arteries after acute myocardial infarction.

Whether angioplasty of occluded vessels after myocardial infarction may have beneficial effects on left ventricular function remains unknown. Patients with a first myocardial infarction and thrombolytic therapy who had an occluded infarct-related vessel at delayed coronary angiography were referred systematically for an elective coronary angioplasty performed between 3 and 4 weeks after the myocardial infarction. All patients underwent stress-redistribution-reinjection thallium-201 single-photon emission computed tomography for myocardial viability assessment. Prior angioplasty, a quantitative evaluation of global and regional left ventricular function, was performed. The study group consisted of 38 patients (aged 57 +/- 10 years); 18 had anterior wall infarctions and 20 inferior wall infarctions, but before angioplasty 3 had a patent artery and were excluded. Angioplasty was successful in 30 patients. At follow-up 13 patients (43%) had an occluded coronary artery. In contrast with patients with an occluded coronary artery at follow-up, those with a patent coronary artery had no left ventricular enlargement and had an improvement in both left ventricular ejection fraction (from 48 +/- 9% to 52 +/- 9.8%, p = 0.002) and regional wall motion index (delta = +0.95 SD, p <0.01). In patients with a patent vessel at follow-up, there was a positive correlation between the number of myocardial viable segments and improvement of the infarct zone wall motion (r = 0.52; p = 0.035), and the number of necrotic segments at baseline was positively correlated to the 4-month changes in end-diastolic volume indexes (r = 0.6; p = 0.04). Thus, elective revascularization of occluded coronary arteries with viable myocardium after myocardial infarction improves left ventricular function and lessens remodeling if the artery remains patent during follow-up.

Aged↗

PubMed1996

[Treatment by angiotensin converting enzyme inhibitors after myocardial infarction. What did the clinical trials teach us?].

Most clinical trials of angiotensin converting enzyme inhibitors after myocardial infarction have shown an improved outcome with reduction of morbidity and mortality. In comparable groups of patients, the results are concordant with a decrease in mortality which is all the more significant and early in severe infarction with serious haemodynamic consequences. The clinician has a new arm in his therapeutic arsenal either for use in the acute phase of all cases of myocardial infarction but for only a short period of 4 to 6 weeks after which the treatment is withdrawn when the anatomical sequellae are more moderate, or for use in selected cases for longer periods (patients with severe infarction with cardiac failure and/or severe left ventricular dysfunction). The second attitude has the advantage of treating a selected population which will derive greater benefits. In all cases, treatment should be started orally at low doses, and the dose must be increased rapidly do attain the target dosage under close clinical and biological surveillance. When the classical contraindications are respected, ACE inhibitors seem to be well tolerated even at the relatively high dosages recommended after myocardial infarction. Hypotension and, more rarely, renal failure, are the two most common complications leading to withdrawal of treatment, but neither of these side effects was associated with increased mortality in any of the clinical trials. The mechanisms by which ACE inhibitors exert these beneficial effects after myocardial infarction are not only their haemodynamic effects and their role in ventricular remodelling, but also probably by a vascular protective action which, if confirmed, would further increase the indications of this therapeutic class in cardiovascular diseases.

Angiotensin-Converting Enzyme Inhibitors↗